- ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-blind Trial to Demonstrate Similar Efficacy, Safety, and Immunogenicity of FYB206 (Keytruda Biosimilar Candidate) in Comparison to Keytruda (Pembrolizumab) as an Add-on to Chemotherapy in Treatment-naïve Patients with Metastatic Non-squamous Non-small Cell Lung Cancer (LOTUS)
This study is comparing a new medication called FYB206 to a commonly used lung cancer drug, Keytruda. We want to see if FYB206 works just as well and is as safe for people with a certain type of advanced non-small cell lung cancer when given with chemotherapy.
Romania · Bulgaria · Poland - recruitingPHASE1, PHASE2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
This study is testing a new drug, rezatapopt, for advanced cancers with a specific gene change (TP53 Y220C). It's also looking at rezatapopt with another drug, pembrolizumab, to see how safe and effective they are. It’s for people who have already had cancer treatment.
United States · Australia · France - active not recruitingPHASE1
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
This study is testing a new medicine, IOA-244, for people with certain advanced cancers, including lymphoma and melanoma. It aims to see if the medicine is safe and if it can help the body's immune system fight cancer, both alone and with other treatments.
Italy · United Kingdom - active not recruitingPHASE1
Phase I Trial of Defactinib and VS-6766.
This study is testing two new drugs, Defactinib and VS-6766, for patients with advanced cancers like certain lung, ovarian, womb, and pancreatic cancers. It aims to find the safest dose and see how well the combination works.
United Kingdom - recruitingPHASE1, PHASE2
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
This study is looking at a new drug called MCLA-158 for advanced cancers like bowel and head and neck cancer. It aims to find the safest dose and see how well it works alone or with other treatments. It's for patients whose cancer has spread or come back.
United States · Belgium · France - recruitingPHASE3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
This study is testing a new drug, daraxonrasib, for people with a specific type of advanced lung cancer (non-small cell lung cancer, or NSCLC) that has a RAS gene change. It compares the new drug to an existing chemotherapy, docetaxel, to see if it works better or has fewer side effects.
United States · Australia · Belgium - recruitingPHASE1
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
This study is testing a new drug, OKN4395, alone and with an existing cancer treatment, pembrolizumab, for various solid tumours. The main goals are to check its safety, how well it's tolerated, and if it helps fight cancer.
United States · Australia · United Kingdom - recruitingPHASE3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
This study looks at new ways to treat advanced squamous non-small cell lung cancer. It combines standard treatment (Pembrolizumab, Carboplatin, Paclitaxel/Nab-paclitaxel) with a new drug, sac-TMT, to see if it helps people live longer.
United States · Argentina · Austria - recruitingPHASE1, PHASE2
A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies
This study is testing a new medicine called EP0031 for advanced cancers caused by problems with a gene called RET. It aims to see if EP0031 is safe, what side effects it causes, and how well it works, especially for a type of lung cancer called NSCLC.
United States · France · Germany - active not recruitingPHASE3
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
This study offers continued access to treatments like Avelumab for people who were in earlier Pfizer studies and are still benefiting. It focuses on several cancers and ensures ongoing care and tracking of their health.
United States · Australia · Belgium - active not recruitingPHASE3
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
This study is testing a new combination of treatments for adults with advanced lung cancer (NSCLC) that hasn't spread to the brain or spine and doesn't have certain genetic changes. It compares this new treatment to a standard one, hoping it works better.
United States · Austria · Brazil - recruitingPHASE1, PHASE2
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
This study is testing a new medicine called S241656 for people with certain advanced cancers, including lung, bowel, and pancreatic cancers. It aims to find a safe and effective dose, either alone or with other treatments, for cancers with specific genetic changes.
United States · Denmark · Hong Kong - recruitingNA
The CyberChallenge Trial How Much is Too Much - What is the Role of Cyberknife Radiosurgery in Patients With Multiple Brain Metastases?
This study looks at how best to treat people with several brain tumours, often from other cancers. It compares two types of radiation treatment to see which offers a better quality of life and helps people live longer, while also being easier to tolerate.
Germany - recruiting
Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)
This study is looking at a new way to give radiotherapy using a special machine called ETHOS. It aims to make radiotherapy more accurate by adjusting treatment daily for cancers like prostate or head and neck, potentially improving how well it works and reducing side effects.
Germany - recruitingPHASE2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
This study is testing a new oral medicine, APL-101, for people with advanced cancers. It focuses on lung cancer and other solid tumours where specific genetic changes linked to a protein called MET are found. Researchers want to see how well it works and if it's safe.
United States · Australia · Canada - active not recruitingPHASE2
Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)
This study looks at new ways to treat a type of lung cancer that can be removed by surgery. It combines standard chemotherapy with a new immunotherapy drug (durvalumab) and different types of radiation therapy to see if this mix works better.
Germany · Switzerland - recruiting
Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer
This study looks at how well a treatment combining chemotherapy and amivantamab works for advanced lung cancer with specific gene changes. It helps us understand real-life results and safety for people already receiving this treatment through early access programs.
France - recruiting
Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy
This study looks at combining special cancer drugs (PD-1/PD-L1 inhibitors) with radiation. It aims to see how well this works for various cancers and if we can find new ways to predict who will benefit most from this treatment.
Germany - recruitingPHASE1, PHASE2
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
This study is for people with a type of advanced lung cancer where standard treatments haven't worked or aren't suitable. It's testing a new drug, STX-721/PFL-721, to see how safe it is and if it can help by targeting specific changes in cancer cells.
United States · France · Germany - active not recruitingPHASE2
Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study
This study looks at whether it's safe and effective to continue a lung cancer drug called osimertinib (Tagrisso) while also having radiotherapy. It focuses on people with a specific type of lung cancer that has a particular genetic change.
Germany - recruitingPHASE1, PHASE2
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
This study is testing a new drug called TUB-030 for adults with advanced solid cancers. Researchers want to see if it's safe, how well it works, and find the right dose. It's a first step to understand if TUB-030 could be a future treatment.
United States · Canada · Romania